PepGen Inc. (PEPG) |
|
15.23 -1.65 (-9.77%)
|
03-24 16:00 |
|
Open: |
20 |
Pre. Close: |
16.88 |
|
High:
|
20 |
Low:
|
14.27 |
|
Volume:
|
41,759 |
Market Cap:
|
360(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 4:28:45 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 20.01 One year: 23.36 |
| Support: |
Support1: 12.51 Support2: 10.4 |
| Resistance: |
Resistance1: 17.13 Resistance2: 20 |
| Pivot: |
15.81 |
| Moving Average: |
MA(5): 16.51 MA(20): 15.73
MA(100): 15.09  MA(250): 0 |
| MACD: |
MACD(12,26): 0 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 57.7 %D(3): 70.9 |
| RSI: |
RSI(14): 46 |
| 52-week: |
High: 20 Low: 4.32 |
| Average Vol(K): |
3-Month: 47 (K) 10-Days: 41 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ PEPG ] has closed above bottom band by 39.0%. Bollinger Bands are 49.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
20.05 - 20.15 |
20.15 - 20.23 |
|
Low:
|
14.07 - 14.17 |
14.17 - 14.25 |
|
Close:
|
15.08 - 15.24 |
15.24 - 15.37 |
|
Company Description |
|
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts. |
Headline News |
Sat, 25 Mar 2023
PepGen Inc (PEPG) Q4 2022 Earnings Call Transcript - Finnoexpert
Sat, 25 Mar 2023
PepGen (NASDAQ:PEPG) Given New $22.00 Price Target at ... - MarketBeat
Fri, 24 Mar 2023
Why Scholastic Shares Are Trading Lower By 23%? Here Are Other ... - Investing.com UK
Thu, 23 Mar 2023
PepGen Reports Fourth Quarter and Full Year 2022 Financial ... - GlobeNewswire
Thu, 23 Mar 2023
PepGen Inc (PEPG) is higher by 12.59% in a Week, Should You Sell? - InvestorsObserver
Sat, 18 Mar 2023
PepGen (PEPG) Set to Announce Quarterly Earnings on Thursday - MarketBeat
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
24 (M) |
| Shares Float |
9 (M) |
|
% Held by Insiders
|
32 (%) |
|
% Held by Institutions
|
79.2 (%) |
|
Shares Short
|
209 (K) |
|
Shares Short P.Month
|
264 (K) |
Stock Financials |
|
EPS
|
-3.06 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
8.18 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-20.4 |
|
Return on Equity (ttm)
|
-36.9 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-2.46 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-52 (M) |
|
Levered Free Cash Flow
|
-31 (M) |
Stock Valuations |
|
PE Ratio
|
-4.98 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
1.85 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-6.94 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
